Acceptable Multi-user Biodegradable Extended Release (AMBER) Implant System for HIV Prevention

用于预防艾滋病毒的可接受的多用户可生物降解缓释 (AMBER) 植入系统

• 批准号: 10663830
• 负责人: Leah Johnson
• 金额: $ 92.15万
• 依托单位: RESEARCH TRIANGLE INSTITUTE
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-08-20 至 2025-07-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10663830
• 关键词: AIDS prevention; Address; Adherence; Adverse reactions; African American; Alabama; Animal Model; Anti-Retroviral Agents; Antiviral Agents; Area; Behavioral Research; Biodegradation; Bypass; California; Centers for Disease Control and Prevention (U.S.); Characteristics; Development; Devices; Dose; Drug Delivery Systems; Drug Formulations; Drug Kinetics; Engineering; Epidemic; Ethnic Origin; Excision; Exposure to; Focus Groups; Formulation; Future; Gender; Geographic Locations; Geography; Goals; HIV; Implant; In Vitro; Injectable; Integrase Inhibitors; International; Intervention; Interview; Kinetics; Latino; Lead; Mechanics; Medical; Medicine; Modeling; Modification; Mucous Membrane; Nucleosides; Online Systems; Pattern; Pharmaceutical Preparations; Pharmacologic Substance; Polymers; Population; Property; Public Health; RNA-Directed DNA Polymerase; Rectum; Research; Research Institute; Risk; Safety; San Francisco; Science; Sex Orientation; Social Behavior; Surveys; System; Tail; Technology; Toxic effect; Trocars; United States; United States National Institutes of Health; Universities; Vagina; Woman; biodegradable polymer; cis-female; clinical translation; copolymer; design; dosage; drug release kinetics; efficacy evaluation; experimental study; exposure route; fabrication; forgetting; gender diversity; improved; in vivo; in vivo Model; industry partner; informant; inhibitor; innovation; insight; manufacturing process; mechanical properties; men who have sex with men; multidisciplinary; nonhuman primate; novel; penis; pre-exposure prophylaxis; preclinical study; preference; product development; programs; prototype; racial minority population; rectal; safety study; subcutaneous; success; technology development; transgender women; young men who have sex with men

PROJECT SUMMARY/ABSTRACT The overarching goal of this proposed program is to develop an innovative, end-user informed HIV pre- exposure prophylaxis (PrEP) product as an Acceptable Multi-user Biodegradable Extended Release (AMBER) implant. The implant technology addresses multiple challenges with current PrEP drug delivery systems (DDS) by offering beneficial attributes: user-independence and discretion of use, zero-order (sustained) release, long-term protection (≤1 year), retrievability and biodegradation of the polymeric implant. We propose to engineer the implant to be retrievable throughout the drug delivery period, in the case of adverse reactions or an end-user’s wish to discontinue. Otherwise, the AMBER implant will remain in-place and biodegrade after drug depletion. Uniquely, the AMBER implant decouples drug delivery features from biodegradation properties, which enables zero-order kinetics of drug release. The AMBER program addresses the goals of this National Institutes of Health (NIH) opportunity (RFA-AI-19-063) for the development of new and innovative sustained/extended release (SER) DDS for HIV PrEP with novel (non- tenofovir based) antivirals (ARV). We will inform implant development by eliciting preference insights from diverse gender, sexual orientation, and ethnic/racial minority populations in two priority geographical areas under “Ending the HIV Epidemic” initiative in the United States. We propose three specific aims: (1) develop the AMBER implant with polymers optimized for high durability and bioerosion profiles; (2) formulate selected ARVs and evaluate safety, pharmacokinetics, and efficacy of lead AMBER implants in preclinical studies; (3) identify Preferred User Characteristics (PUCs), inform technology development and future deployment of AMBER into practice by conducting iterative socio-behavioral research with Young MSM, cis- and trans- gender women in California and Alabama. We will strive to align PUC and key modifiable attributes during product development: sustained (≤1 year) delivery of novel ARV, polymers designed to optimize biodegradation timescales, incorporation of end-user acceptability information into a Target Product Profile (TPP), and evaluation of efficacy in nonhuman primate model. The AMBER program is milestone-driven and provides defined deliverables to product development efforts to support future needs in clinical translation.

项目总结/文摘